65,437 trials
Diabetes · Diabetes Mellitus, Type 1
Primary: Change in the Percentage of HbA1c — 7.57; 7.58; 7.53; 0.06 Percentage of HbA1c — p=<0.001
Desmoplastic/Nodular Medulloblastoma · Medulloblastoma · Medulloblastoma With Extensive Nodularity
Primary: Progression-free Survival (PFS) — 52.0 percent probability
Myopia · Refractive Errors
Primary: Overall Quality of Vision — 9.2; 8.6 units on a scale
Prostate Cancer
Primary: Progression-free Survival (PFS) in Participants With Hormone Refractory Prostate Cancer (HRPC) Administered LY2181308 Sodium Plus Docetaxel Compared to Docetaxel Alone…
Smoking Cessation · Smoking · Nicotine Dependence
Primary: Change Between Baseline Mean Cigarettes Smoked Per Day and Mean Cigarettes Smoked Per Day During the First 4 Weeks of the Quit Attempt Calculated as Percentage Change…
Hearing Loss, Sensorineural · Cognitive Impairment
Primary: Cognitive Screening Results (Montreal Cognitive Assessment) — 28.69; 22.37; 23.375; 23 score on a scale
Multiple Myeloma
Primary: Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR) — 44.2; 57.1 Percentage of Participants
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations — 8595; 5071 wins — p=0.0006
Post Traumatic Stress Disorder · Attention Deficit Hyperactivity Disorder
Primary: Conners' Adult ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S, Conner et al, 1999) — 75.12; 68.56; 67.79; 72.80 units on a scale
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period — -4.41; -6.14 Units on a scale — p=0.0983
HIV-1 Infection
Primary: Percentage of Participants Maintaining Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL — 90.8; 94.6 Percentage of Participants
Carcinoma, Non-Squamous Non-Small Cell Lung
Primary: Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population…
Ankylosing Spondylitis
Primary: Number of Participants With Adverse Drug Reactions — 101; 15 Participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0 percentage of participants
Allergic Sensitization
Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants